Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred R Hirsch

Showing results (191-200 of 407) with videos related to

Pageof 41
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapySamir E Witta, Robert M Jotte, Katrik Konduri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2009
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohortMarileila Varella-Garcia, Tetsuya Mitsudomi, Yashushi Yatabe, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2012
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studiesLisa Licitra, Stephan Störkel, Keith M Kerr, et al.
Respiratory Research|November 9, 2019
Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancerMengting Zhou, Jun Fan, Zhenyu Li, et al.
Clinical Lung Cancer|July 28, 2016
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung CancerFred R Hirsch, Ramaswamy Govindan, Zanete Zvirbule, et al.
Lung Cancer (Amsterdam, Netherlands)|November 26, 2021
CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancerQian Liu, Meng Qiao, Zoltan Lohinai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
Contributions of KRAS and RAL in non-small-cell lung cancer growth and progressionSunny Guin, Yuanbin Ru, Murry W Wynes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 19, 2017
Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR MutationsXuefei Li, Weijing Cai, Guohua Yang, et al.
Cancers|May 14, 2025
Roles of Annexin A1 Expression in Small Cell Lung CancerÁgnes Paál, David Dora, Ákos Takács, et al.
Clinical Lung Cancer|February 19, 2013
Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinomaDerick H M Lau, James Moon, Angela M Davies, et al.
Pageof 41

Showing results (191-200 of 407) with videos related to

Sort By:
Pageof 41
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2012
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapySamir E Witta, Robert M Jotte, Katrik Konduri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2009
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohortMarileila Varella-Garcia, Tetsuya Mitsudomi, Yashushi Yatabe, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2012
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studiesLisa Licitra, Stephan Störkel, Keith M Kerr, et al.
Respiratory Research|November 9, 2019
Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancerMengting Zhou, Jun Fan, Zhenyu Li, et al.
Clinical Lung Cancer|July 28, 2016
Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung CancerFred R Hirsch, Ramaswamy Govindan, Zanete Zvirbule, et al.
Lung Cancer (Amsterdam, Netherlands)|November 26, 2021
CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancerQian Liu, Meng Qiao, Zoltan Lohinai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
Contributions of KRAS and RAL in non-small-cell lung cancer growth and progressionSunny Guin, Yuanbin Ru, Murry W Wynes, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 19, 2017
Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR MutationsXuefei Li, Weijing Cai, Guohua Yang, et al.
Cancers|May 14, 2025
Roles of Annexin A1 Expression in Small Cell Lung CancerÁgnes Paál, David Dora, Ákos Takács, et al.
Clinical Lung Cancer|February 19, 2013
Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinomaDerick H M Lau, James Moon, Angela M Davies, et al.
Pageof 41